TEVA


Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Can Migraine Asset Still Secure “On-Time” FDA Approval?

Guggenheim’s Rohit Vanjani is reassured from the sidelines on TEVA’s fremanezumab’s prospects to clear an FDA not despite supply plant’s Warning Letter.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Prices Upsized $4.5B Debt Offering

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced that it successfully priced the offering of $4.5 billion of its previously announced senior notes.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Still a Hard Pill to Swallow

This analyst isn’t ready to get bullish on TEVA. Here’s why.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Risky Fundamentals Likely To Just Get Worse This Year

BTIG’s Tim Chiang is out with a bearish case against Teva after last week’s less-than-stellar 2018 guidance reveal.

Teva Pharmaceutical Industries Ltd (ADR) Announces the Launch of Generic Equivalents to Syprine

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) today announced the US launch of its generic equivalents to Valeant’s (NYSE:VRX) 30-year-old drug, Syprine (trientine hydrochloride), used …

Analyst Derek Archila Sizes Up Risks to Teva Pharmaceutical Industries Ltd (ADR) Shares

As Wall Street scrambles away from Teva after a sharp guidance miss for 2018, Oppenheimer’s Derek Archila shares his two (cautious) cents.

Teva Pharmaceutical Industries Ltd (ADR): From a Bull to a Bear; Tim Chiang Is Officially Throwing in the Towel

Generics price erosion; the ghost of debt maturation- BTIG’s Tim Chiang sees too many risks to hope for Teva’s recovery anymore.

Teva Pharmaceutical Industries Ltd (ADR) Gains Some Breathing Room in Its Restructuring Initiative, Says Analyst

Though Guggenheim’s Rohit Vanjani is not surprised by Teva’s amendment of financial leverage covenants, he sees this as a “watch” item.

Teva Pharmaceutical Industries Ltd (ADR) Finalizes the Sale of its Global Women’s Health Business

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced today it has completed the sale of a portfolio of products within its global women’s health …

Teva Pharmaceutical Industries Ltd (ADR) Is Under Siege; How Will Rising Competition Play Out in 2018?

BTIG’s Tim Chiang cautions that Momenta’s generic 40mg Copaxone is not the only rival coming for Teva.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts